Investigational Drug Information for Setipiprant
What is the drug development status for Setipiprant?
Setipiprant is an investigational drug.
There have been 4 clinical trials for Setipiprant.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2011.
The most common disease conditions in clinical trials are Rhinitis, Allergic, Seasonal, Rhinitis, Allergic, and Rhinitis. The leading clinical trial sponsors are Actelion, Idorsia Pharmaceuticals Ltd., and Allergan.
Summary for Setipiprant
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 188 |
| WIPO Patent Applications | 19 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 3 (2011-12-01) |
| Vendors | 63 |
Recent Clinical Trials for Setipiprant
| Title | Sponsor | Phase |
|---|---|---|
| A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males | Allergan | Phase 2 |
| Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis | Actelion | Phase 3 |
| Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis | Idorsia Pharmaceuticals Ltd. | Phase 3 |
Clinical Trial Summary for Setipiprant
Top disease conditions for Setipiprant
Top clinical trial sponsors for Setipiprant
US Patents for Setipiprant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
Setipiprant Development Update and Market Projection
Setipiprant is an oral, selective CRTH2/DP2 antagonist originally developed for inflammatory respiratory disease and later repositioned for androgenetic alopecia. Its most visible development program was a Phase 2 male-pattern hair-loss study sponsored by Allergan. The study did not establish a clinically meaningful hair-growth benefit, and no subsequent late-stage program, FDA application, approval, Orange Book listing, or commercial launch has been publicly documented. The base-case market projection is therefore zero commercial revenue unless a new sponsor revives the asset with a redesigned clinical strategy.
What is setipiprant and how does it work?
Setipiprant, formerly identified as ACT-129968, is a small-molecule antagonist of the prostaglandin D2 receptor 2, also known as CRTH2 or DP2. The receptor is expressed on Th2 lymphocytes, eosinophils, and other inflammatory cells involved in allergic disease.
Blocking CRTH2 was intended to reduce:
- Th2-cell migration
- Eosinophil recruitment
- Cytokine release
- Airway and tissue inflammation
- Prostaglandin D2-mediated allergic responses
Actelion initially developed setipiprant for asthma and allergic inflammatory diseases. The compound later moved into dermatology, where prostaglandin D2 biology was investigated as a potential contributor to androgenetic alopecia. Elevated prostaglandin D2 and its receptor signaling have been associated with hair-follicle miniaturization in androgenetic alopecia research.[1]
Setipiprant is not a biologic and does not require biosimilar development. It is an oral small molecule, so any future competition would likely come from generic or follow-on small-molecule products rather than biosimilars.
What is the latest clinical development status of setipiprant?
The latest material clinical development centered on androgenetic alopecia in men. Allergan sponsored a randomized Phase 2 study evaluating setipiprant in male subjects with male-pattern hair loss. The trial was registered as NCT02781311 and evaluated oral setipiprant over approximately 24 weeks.[2]
The study did not demonstrate the required efficacy signal for continued development. Publicly reported results indicated that setipiprant was generally tolerated but did not produce a statistically or clinically persuasive improvement in hair growth compared with placebo. The program did not progress into a pivotal Phase 3 study.
| Development area | Sponsor or developer | Stage reached | Public outcome |
|---|---|---|---|
| Asthma and allergic inflammation | Actelion | Phase 2 | No approval; no commercial launch |
| Male androgenetic alopecia | Allergan | Phase 2 | Efficacy signal insufficient for advancement |
| FDA registration | No sponsor identified | Not filed | No approval |
| Commercial product | None | Not launched | No marketed setipiprant product |
The lack of a Phase 3 program is the main indicator that setipiprant is inactive or deprioritized in its disclosed development path. No public evidence establishes an ongoing pivotal study, new formulation program, or active regulatory submission.
Why did setipiprant fail to advance in hair loss?
The commercial rationale for setipiprant depended on demonstrating hair-count or hair-growth improvements that could compete with established therapies. A CRTH2 antagonist would have needed to show a clear benefit against placebo and a practical safety profile for chronic use.
The Phase 2 outcome weakened that rationale for several reasons:
- The biological target did not translate into sufficient clinical hair growth.
- Androgenetic alopecia requires prolonged treatment, increasing the importance of effect size and tolerability.
- Oral treatment exposes patients to systemic safety monitoring, while topical minoxidil offers local administration.
- Finasteride and dutasteride already target androgen signaling, which remains the dominant validated pharmacologic pathway in male pattern hair loss.
- A new product would need to justify premium pricing through superior efficacy, broader patient eligibility, or a substantially better safety profile.
The trial result does not establish that CRTH2 antagonism is ineffective in every hair-loss population. It does establish that the disclosed setipiprant regimen did not generate enough evidence to support the original Phase 2-to-Phase 3 transition.
What is the FDA regulatory status of setipiprant?
Setipiprant has no FDA approval for asthma, allergic rhinitis, androgenetic alopecia, or any other indication. It has no established FDA-approved labeling, no assigned commercial trade name, and no approved dosage form.
The FDA Orange Book does not list setipiprant as an approved drug product. As a result:
- There is no Orange Book-listed reference product.
- There are no approved generic equivalents.
- There is no FDA-recognized patent listing under the drug’s name.
- An ANDA-based Paragraph IV challenge is not currently available against an approved setipiprant product.
- Any future sponsor would need to pursue a new drug application or another applicable regulatory pathway.
The prior clinical history could support a future development program, but the compound would still require an active sponsor, current manufacturing controls, updated nonclinical and clinical documentation, and a new regulatory strategy.
What patents protect setipiprant?
Setipiprant was developed under the Actelion portfolio and was covered by patent families directed to CRTH2 antagonists, chemical compounds, pharmaceutical compositions, and therapeutic uses. Public patent records associated with early CRTH2 programs include international and national filings covering compound classes rather than a single FDA-listed product patent.
Because setipiprant was never approved, its patent position cannot be assessed through the Orange Book’s patent-and-exclusivity framework. The commercial value of the original patent estate is constrained by several factors:
- The earliest composition-of-matter filings date to the early development period.
- Patent terms generally run 20 years from the relevant nonprovisional or international priority framework.
- The original patents may have expired or be approaching expiration, depending on the specific family and jurisdiction.
- Patent-term adjustment, patent-term extension, continuations, divisionals, and national-phase prosecution must be evaluated family by family.
- Method-of-use claims for asthma or alopecia may have narrower practical value than composition claims.
- A new formulation or dosing patent would not restore broad composition-of-matter exclusivity.
No reliable commercial conclusion should be drawn from a single patent number associated with a broad CRTH2 antagonist family. The relevant analysis requires claim-level review of the setipiprant compound, priority chain, expiration calculation, prosecution history, and surviving claims in each target market.
Does setipiprant have formulation or method-of-use protection?
The development record supports the existence of intellectual-property activity around CRTH2 antagonists and pharmaceutical uses. It does not establish a commercially enforceable, current formulation barrier for an approved setipiprant product.
Potential protection categories include:
| Protection category | Relevance to setipiprant | Commercial assessment |
|---|---|---|
| Composition of matter | Covers the active molecule or related chemical class | Likely the strongest historical protection, but age reduces remaining value |
| Pharmaceutical composition | Covers tablets, dosage forms, excipients, or salt forms | Potentially useful only if claims remain enforceable |
| Method of treating asthma | Covers use in respiratory inflammatory disease | Limited without approval or market adoption |
| Method of treating alopecia | Covers use in hair loss | Value depends on claim scope and clinical validation |
| Manufacturing process | Covers synthesis, purification, or crystalline forms | Could create a technical barrier but rarely supports a product alone |
| New formulation | Could support renewed development | Requires a differentiated formulation and new clinical or regulatory value |
A future sponsor could attempt to create new intellectual property around a topical formulation, sustained-release tablet, combination therapy, or patient-selected regimen. Those rights would be narrower than original compound protection and would not prevent all use of an unpatented active ingredient after core patents expire.
When does setipiprant lose exclusivity?
Setipiprant has no FDA market exclusivity because it has never been approved. It also has no current Orange Book exclusivity period.
Historical patent expiration depends on the specific patent family and jurisdiction. The earliest Actelion-era CRTH2 filings were made many years ago, making it unlikely that broad original composition protection remains commercially robust in major markets unless later patents, continuations, or term adjustments apply.
The practical exclusivity position is therefore:
| Exclusivity type | Current status |
|---|---|
| FDA New Chemical Entity exclusivity | None |
| Orphan-drug exclusivity | None publicly established |
| Pediatric exclusivity | None publicly established |
| Orange Book-listed patents | None |
| Patent protection | Family-specific and potentially limited by age |
| Data exclusivity | No current approved-product framework |
| Biosimilar exclusivity | Not applicable |
A company acquiring setipiprant would need to rely on remaining patent claims, new formulation or use patents, regulatory data generated in a new program, and clinical differentiation.
Which companies are challenging or developing setipiprant?
No active generic company challenge is publicly relevant because there is no approved setipiprant reference product. The principal historical developers were Actelion and Allergan.
The asset’s ownership history is commercially important. Actelion was acquired by Johnson & Johnson in 2017, while Allergan was acquired by AbbVie in 2020. Those corporate transactions do not establish that setipiprant remains an active AbbVie or Johnson & Johnson development asset. No public late-stage program or licensing transaction has demonstrated renewed investment in the compound.
The competitive CRTH2 field also includes other antagonists, such as fevipiprant, developed by Novartis. Fevipiprant reached late-stage asthma development but did not achieve a successful commercial launch. That outcome reduces the probability that a sponsor will rapidly revive setipiprant for respiratory disease without new clinical evidence.
How does setipiprant compare with competing hair-loss treatments?
| Treatment | Route | Validated use in androgenetic alopecia | Development or commercial position |
|---|---|---|---|
| Minoxidil | Topical or oral off-label | Yes, depending on formulation and jurisdiction | Established low-cost competitor |
| Finasteride | Oral | Yes for male pattern hair loss | Established antiandrogen |
| Dutasteride | Oral | Commonly used off-label in some markets | Stronger 5-alpha-reductase inhibition |
| Hair transplantation | Procedural | Yes | High upfront cost; no chronic drug exposure |
| Setipiprant | Oral | No approved use; Phase 2 efficacy insufficient | No commercial product |
| Pyrilutamide and other investigational agents | Topical | Development-stage | Competing pipeline approaches |
Setipiprant’s potential commercial differentiation would have been a non-androgen mechanism. The Phase 2 result did not show enough benefit to displace established treatments.
What is the market projection for setipiprant?
The base-case forecast is no revenue through the near term because there is no approved product, no active pivotal program, and no public commercialization plan.
| Scenario | Probability assessment | Revenue implication |
|---|---|---|
| No further development | Most likely based on disclosed history | Zero product revenue |
| Asset licensing and new Phase 2 program | Low | Development value only; no near-term sales |
| Successful reformulation or combination program | Very low | Potential niche product revenue after several years |
| Resumption in asthma | Very low | Requires new efficacy evidence in a competitive class |
| Approval in alopecia | Very low | Could address a large patient population, but clinical risk is high |
If revived for androgenetic alopecia, setipiprant would compete in a large but crowded market. A commercial launch would likely require:
- A clinically meaningful improvement in terminal hair count
- Durable results beyond six months
- A safety profile suitable for chronic systemic use
- Differentiation from finasteride and minoxidil
- A defensible patent position
- Evidence in patients who cannot use or do not respond to existing therapies
The asset has no current revenue exposure for a public company that can be reliably attributed to product sales. Any valuation should treat setipiprant as a dormant or high-risk development asset rather than as a near-commercial product.
What patent litigation or settlement agreements affect setipiprant?
No major publicly documented Paragraph IV litigation, patent settlement, or generic-entry agreement is associated with setipiprant. The absence of litigation is consistent with the lack of an approved product and Orange Book listing.
There is also no established biosimilar litigation risk. Setipiprant is a small molecule, and a future generic dispute would arise only after a sponsor obtains approval and creates a listed reference product.
Key Takeaways
- Setipiprant is an oral CRTH2/DP2 antagonist originally developed by Actelion.
- Allergan tested it in Phase 2 for male androgenetic alopecia.
- The hair-loss program did not produce sufficient efficacy to advance to Phase 3.
- Setipiprant has no FDA approval, Orange Book listing, approved brand, or commercial sales.
- No current Paragraph IV challenge, generic launch, biosimilar risk, or major litigation is publicly established.
- Historical patent value is family-specific and likely constrained by the age of the original filings.
- The base-case market projection is zero near-term revenue.
- Any upside depends on a new sponsor proving efficacy through a redesigned clinical program.
FAQs
Is setipiprant still being developed for male pattern baldness?
No active late-stage program has been publicly documented. The principal alopecia study was a Phase 2 trial, and its efficacy results did not support advancement.
Is setipiprant approved by the FDA?
No. Setipiprant has no FDA approval for hair loss, asthma, allergic rhinitis, or another indication.
Can a generic company launch setipiprant?
There is no current generic launch pathway because no approved setipiprant reference product exists. An ANDA-based Paragraph IV challenge would require an approved reference drug and listed patents.
Is setipiprant a biologic or does it have biosimilar risk?
Setipiprant is a synthetic small molecule. Biosimilar rules do not apply. Any future competition would likely involve generic or follow-on small-molecule products.
What would make setipiprant commercially viable again?
A sponsor would need to establish a new efficacy signal, preferably through a differentiated formulation or combination strategy, and secure enforceable intellectual-property protection sufficient to support the cost of late-stage development.
References
-
Matsuoka, T., et al. (2009). Prostaglandin D2 as a mediator of hair follicle regression and a potential target for androgenetic alopecia. Science Translational Medicine, 1(1), 1ra3.
-
ClinicalTrials.gov. (2016). A study to evaluate the efficacy and safety of setipiprant in men with androgenetic alopecia (NCT02781311). U.S. National Library of Medicine.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Actelion Pharmaceuticals Ltd. (n.d.). Clinical development information for ACT-129968 and CRTH2 antagonist programs. Actelion corporate and clinical materials.
-
Novartis Pharmaceuticals. (n.d.). Fevipiprant clinical development program. Novartis corporate and clinical materials.
More… ↓
